Activities of sordarins in murine histoplasmosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1716-1718

  Graybill, John R ^a,b,d   Najvar, Laura ^a   Fothergill, Annette ^b   Bocanegra, Rosie ^a   Gomez De Las Heras, Federico ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (Spain)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GM 193663A; GM 211676; GM 237354A; SORDARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LUNG; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 0032799324     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1716     Document Type: Article

References (17)

1. Aliouat, E. M., P. Aviles, E. Dei-Cas, E. Herreros, L. Dujardin, and D. Gargallo-Viola. 1998. In vitro pharmaodynamic [sic] parameters of sordarin derivatives in comparison with marketed compounds against rat-derived Pneumocystis carinii, abstr. J-15, p. 454. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Alvarez, M. E., E. Herreros, A. Sanchez-Sousa, D. Gargallo-Viola, and F. Baquero. 1998. In vitro activity of sordarins in combination with other systemic antifungal agents against Candida albicans, Aspergillus spp., and Scedosporium apiospermun [sic], abstr. J-12, p. 454. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Aviles, P., C. Falcoz, C. Efthymiopoulos, R. San Roman, A. Martinez, E. Jimenez, M. S. Marriott, A. Bye, F. Gomez De Las Heras, and D. Gargallo-Viola. 1998. Pharmacokinetic/pharmacodynamic (PK/PD) study of sordarin derivatives in a lethal C. albicans infection in mice, abstr. J-74, p. 472. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Capa, L., A. Mendoza, J. L. Lavandera, F. Gómez de las Heras, and J. F. García-Bustos. 1998. Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Chemother. 42:2694-2699.
5. Domínguez, J. M., V. A. Kelly, O. S. Kinsman, M. S. Marriott, F. Gómez de las Heras, and J. J. Martín. 1998. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42:2274-2278.
6. Domínguez, J. M., and J. J. Martín. 1998. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob. Agents Chemother. 42:2279-2283.
7. Gomez, M. G., and J. F. Garcia Bustos. 1998. Ribosomal P-protein stalk function is targeted by sodarin antifungals. J. Biol. Chem. 273:25041-25044.
8. Herreros, E., C. M. Martinez, M. J. Almela, M. S. Marriott, F. Gomez de las Heras, and D. Gargallo-Viola. 1998. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. 42:2863-2869.
9. Johnson, P. C., N. Khardori, A. F. Najjar, F. Butt, P. W. A. Mansell, and G. A. Sarosi. 1988. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am. J. Med. 85:152-158.
10. McKinsey, D. S., M. R. Gupta, M. R. Driks, D. L. Smith, and M. O'Connor. 1992. Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy. Am. J. Med. 92:225-227.
11. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeasts: approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Wheat, J. 1994. Histoplasmosis: recognition and treatment. Clin. Infect. Dis. 19(Suppl. 1):S19-S27.
13. Wheat, J., R. Hafner, A. H. Korzun, M. T. Limjoco, P. Spencer, R. A. Larsen, F. M. Hecht, W. Powderly, and AIDS Clinical Trial Group. 1995. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98:336-342.
14. Wheat, L. J. 1992. Histoplasmosis in Indianapolis. Clin. Infect. Dis. 14(Suppl. 1):S591-S599.
15. Wheat, L. J., R. Hafner, M. Wulfsohn, P. Spencer, K. Squires, W. Powderly, B. Wong, M. G. Rinaldi, M. Saag, R. Hamill, R. Murphy, P. A. Connolly-Springfield, N. Briggs, S. Owens, and NIAID Clinical Trials and Mycoses Study Group. 1993. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118:610-616.
16. Wheat, L. J., T. G. Slama, and M. L. Zeckel. 1985. Histoplasmosis in the acquired immune deficiency syndrome. Am. J. Med. 78:203-210.
17. Zamarro, M. T., J. J. Martin, and J. M. Dominguez. 1998. Sordarins inhibit Aspergillus fumigatus protein synthesis, abstr. J-83, p. 474. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.